Latest Takeda Pharmaceutical Stories
CHICAGO, June 22, 2012 /PRNewswire/ -- Zacks Equity Research highlights Discover Financial Services (NYSE:DFS) as the Bull of the Day and POSCO (NYSE:PKX) as the Bear of the Day. In addition, Zacks Equity Research provides analysis AstraZeneca plc (NYSE:AZN), Bayer (OTC:BAYRY) and Takeda Pharmaceutical (OTC:TKPYY). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678. Here is a synopsis of all...
PHILADELPHIA, May 8, 2012 /PRNewswire/ -- Today, H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Global Research & Development Center Inc., U.S., presented data which demonstrated significant improvements in overall symptoms of depression in elderly patients taking Lu AA21004, an investigational compound for the treatment of major depressive disorder (MDD). This study was presented at the 2012 American Psychiatric Association (APA) Annual Meeting in Philadelphia....
NEW YORK, May 10 /PRNewswire-FirstCall/ -- BNY Mellon, the global leader in asset management and securities servicing, has been appointed by Takeda Pharmaceutical Company Limited (Takeda) as the depositary bank for its sponsored American depositary receipt (ADR) program. Each Takeda ADR represents one-half of a common share and trades on the over-the-counter (OTC) market under the symbol TKPYY. Takeda's common shares trade on the Tokyo Stock Exchange as well as four other exchanges in...
Research and Markets (http://www.researchandmarkets.com/research/121eac/evolving_trends_in) has announced the addition of Decision Resources, Inc.'s new report "Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances" to their offering. This report features interviews with top executives and industry experts, who offer insight into current alliances and contribute to a broad perspective on the drivers of current licensing practices. As the...
Takeda Pharmaceutical has announced that Takeda Pharmaceuticals North America and Takeda Global Research & Development Center merged with Tap Pharmaceutical Products, forming one of the top 15 pharmaceutical companies in the US. The merger is a result of the conclusion of a 30-year joint venture between Takeda Pharmaceutical Company and Abbott announced March 19, 2008. According to terms previously announced, Takeda received the rights to Tap's product Prevacid, its non-Lupron related...
Takeda Pharmaceutical and Takeda Bio Development Center have submitted a new drug application of anti-cancer agent, panitumumab for the treatment of patients with progressed or relapse colorectal cancer to the Ministry of Health Labour and Welfare in Japan. Panitumumab is a fully-human monoclonal antibody which binds to epidermal growth factor receptor and suppresses tumor growth. It shows a low incidence of allergic reaction upon and also after administration as it is a fully-human...
Takeda Pharmaceutical and Abbott Laboratories have announced the imminent conclusion of their joint venture, TAP Pharmaceutical Products. The value of TAP has become questionable in recent years, and the decision to end the partnership is expected to be a positive strategy for both parties. TAP's flagship drugs are to be divided between both companies. Japanese pharmaceutical company Takeda Pharmaceutical and US-based Abbott Laboratories are to conclude their joint venture, Takeda-Abbott...
